Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
sales@csnpharm.com
IL Receptor
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN10040 | YM-90709 | 163769-88-8 | YM-90709 is a competitive and selective IL-5 receptor antagonist with IC50 value ranging in 0.45 - 1 mM. |
| CSN12018 | Suplatast Tosylate | 94055-76-2 | Suplatast Tosylate is an inhibitor of Th2 cytokine synthesis which can attenuate IL-2, IL-5 and IL-13 production and has no effect on IFN- production. |
| CSN20532 | MK-571 | 115104-28-4 | MK-571 sodium is a selective orally active CysLT1 receptor antagonist which blocks the binding of LTD4 but not LTC4 to human and guinea pig lung membranes with Ki values of 022 nM and 21 nM respectively |
| CSN22032 | IX 207-887 | 98320-39-9 | IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1). |
| CSN22936 | IL-1R Antagonist | 566914-00-9 | IL-1R antagonist is a peptide mimic of the myeloid differentiation primary response gene 88 (MyD88) that changes the interaction of MyD88 and IL-1 receptor type I. |
| CSN22931 | GIBH-130 | 1252608-59-5 | GIBH-130 can suppress IL-1 secretion via activating microglia with IC50 of 34 nM and has effect on neuroinflammation |
| CSN21215 | Esonarimod | 101973-77-7 | Esonarimod is an antirheumatic drug and IL-1 inhibitor. |
| CSN10460 | Disulfiram | 97-77-8 | Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram acts as an allosteric inhibitor of MERS-CoV PLpro but as a competitive (or mixed) inhibitor of SARS-CoV PLpro. |
| CSN16710 | Diacerein | 13739-02-1 | Diacerein is a symptomatic slow-acting medicine in osteoarthritis which can reduce the level of IL-1 receptors leading to fewer receptors to form heterodimer complexes. |
| CSN22771 | CP 424174 | 210825-31-3 | CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
